お知らせ • Dec 24
Telomir Pharmaceuticals, Inc. Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson's Disease
Telomir Pharmaceuticals, Inc. announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders. The announcement marks an important step forward in Telomir's mission to address critical unmet medical needs while continuing to explore transformative therapies. Recent preclinical in vitro studies conducted by Recipharm and Smart Assays have demonstrated Telomir-1's exceptional binding affinity for copper ions, highlighting its ability to selectively interact with and regulate copper metabolism. Additionally, Telomir-1's capability to bind and exchange key ions, including copper, iron, and zinc, emphasizes its unique profile and positions it as a promising candidate for further research. These findings form a strong foundation for investigating Telomir-1's potential in addressing Wilson's disease, a rare genetic disorder characterized by excessive copper accumulation that can result in significant damage to the liver, brain, and other vital organs. Wilson's disease is a rare genetic disorder that affects approximately 1 in 30,000 individuals worldwide. The condition is caused by mutations in the ATP7B gene, which impair the body's ability to properly regulate copper metabolism. As a result, copper accumulates to toxic levels, particularly in the liver and brain, leading to severe and potentially life-threatening complications, including liver failure, neurological damage, and psychiatric disorders. Left untreated, Wilson's disease is fatal. Current treatments for Wilson's disease, such as chelating agents (e.g., penicillamine and trientine) and zinc therapy, are primarily aimed at reducing copper levels in the body. While these treatments can be effective, they come with significant drawbacks, including: Chelating agents often cause severe side effects, including kidney damage, bone marrow suppression, and gastrointestinal issues. Additionally, these drugs require lifelong adherence, which can be burdensome for patients. Zinc therapy works by preventing copper absorption in the gut but can result in side effects like anemia, gastrointestinal discomfort, and reduced effectiveness over time. The limitations of current therapies underscore the urgent need for new treatment options that address the root cause of Wilson's disease while minimizing side effects. Telomir-1's copper binding properties hold the potential to offer a safer, more effective alternative that directly targets the underlying mechanisms of the disease. The designation of Wilson's disease as a rare and life-threatening condition also positions it as a candidate for orphan drug designation, which could accelerate development timelines and provide additional regulatory and financial incentives. Earlier this year, Telomir partnered with Midwest Veterinary Services to launch a planned large-scale study on osteoarthritis in dogs. While only the safety phase of the study was completed-showing no adverse effects-the Company chose to discontinue the study. This decision was based on the requirement to induce osteoarthritis in the dogs, a practice that conflicted with the new management's commitment to the Company's mission and values. Instead, the Company is now in discussions with a well-known veterinary institution to design a new study that will recruit elderly dogs who naturally suffer from osteoarthritis. As such, Telomir is committed to obtaining an INAD (Investigational New Animal Drug) application for pets while progressing toward an IND (Investigational New Drug) application for humans. Building on these results, Telomir is planning and advancing studies to expand the therapeutic potential of Telomir-1. Key ongoing initiatives include: Wilson's Disease Study: Investigating Telomir-1's effects on copper regulation in preclinical models. Type 2 Diabetes Studies: After the success achieved with the zebrafish model, Telomir is currently conducting a rat diabetic model to further strengthen the data on Telomir-1's efficacy in reversing key metabolic parameters. Progeria Research: Examining Telomir-1's impact on accelerated aging and telomere function. Cancer Models: Exploring anti-cancer applications using xenograft studies. Alzheimer's Disease: Investigating Telomir-1 for its potential to mitigate cognitive decline and neurodegeneration associated with Alzheimer's. Metal Toxicity: Exploring Telomir-1's role in addressing metal toxicity, which occurs when metals like copper, iron, or lead accumulate to harmful levels in the body. Metal toxicity can disrupt cellular function, lead to oxidative stress, and contribute to chronic and age-related diseases. By regulating metal levels, Telomir-1 aims to restore cellular balance and reduce associated health risks. DNA Methylation Analysis: Investigating Telomir-1's role in modulating DNA methylation rates, which influence gene expression and play a key role in aging and disease progression.DNA methylation, the addition of chemical groups to DNA, can disrupt normal gene function when dysregulated, contributing to various chronic and age-related diseases. By addressing these epigenetic changes, Telomir-1 aims to restore healthy gene expression patterns.
